summary Objective: Gout is the most common arthritis in adults. Despite the availability of valid therapeutic options, the management of patients with gout is still suboptimal. The Italian Society of Rheumatology (SIR) aimed to update, adapt to national contest and disseminate the 2006 EULAR recommendations for the management of gout. Methods: The multidisciplinary group of experts included rheumatologists, general practitioners, internists, geriatricians, nephrologists, cardiologists and evidence-based medicine experts. To maintain consistency with EULAR recommendations, a similar methodology was utilized by the Italian group. The original propositions were translated in Italian and priority research queries were identified through a Delphi consensus approach. A systematic search was conducted for selected queries. Efficacy and safety data on drugs reported in RCTs were combined in a meta-analysis where feasible. The strength of recommendation was measured by utilising the EULAR ordinal and visual analogue scales. Results: The original 12 propositions were translated and adapted to Italian context. Further evidences were collected about the role of diet in the non-pharmacological treatment of gout and the efficacy of oral corticosteroids and low-dose colchicine in the management of acute attacks. Statements concerning uricosuric treatments were withdrawn and replaced with a proposition focused on a new urate lowering agent, febuxostat. A research agenda was developed to identify topics still not adequately investigated concerning the management of gout. Conclusions: The SIR has developed updated recommendations for the management of gout adapted to the Italian healthcare system. Their implementation in clinical practice is expected to improve the management of patients with gout.
G out is the the most common arthritis in adults with a prevalence of between 0.9% in Italy and 3.9% in the USA and with an increasing incidence in Italy and other developed countries (1, 2) . Apart from its high frequency, gout is associated with disability, lower quality of life and increased mortality and therefore represents an everincreasing public health concern (3) (4) (5) . Despite the current in-depth knowledge and the availability of valid therapeutic options in gout, the management of patients with gout is still largely suboptimal (6) . A fundamental prerequisite of gout is hyperuricaemia which is defined as the presence of serum uric acid levels above 6.8 mg/dL (404 µmol/L) which approximately mark the saturation point of monosodium urate (MSU) at physiological temperature and pH (7) . The pathophysiological model portrays, in the presence of hyperuricaemia, the intra-articular deposition of MSU crystals which is responsible for the onset of an acute attack and chronic arthropathy. The management of patients with gout is based on this simplified model and thus implies the control of risk factors related to hyperuricaemia, the effective and rapid control of acute attacks and the persistent reduction of serum MSU levels. These 3 intervention levels represent the basic principles of the 2006 EULAR recommendations on the management of gout compiled by a task force of European experts (8) . The Italian Society of Rheumatology (SIR) has deemed imperative the adaptation, updating and dissemination of the EULAR recommendations for gout. This document is intended for rheumatologists, general practitioners, internists, geriatricians, nephrologists, cardiologists and all healthcare professionals involved in the management of patients with gout.
n MATERIALS AND METHODS
A multidisciplinary group of experts has been appointed by the SIR in order to update and adapt to Italian context the 2006 EULAR recommendations on the management of patients with gout (8) . The group of experts who have accepted to participate included rheumatologists and specialists from various scientific societies involved in the diagnosis and treatment of patients affected by gout such as nephrology, internal medicine, geriatrics, cardiology and general medicine. The objectives of the task force were the following: translation of the recommendations, adaptation to the Italian pharmaceutical formulary (taking in consideration the available drugs and new therapeutic options), identification of priority queries for further analysis, collection of evidence and its critical interpretation, definition of propositions based on the merger of the best available evidence and expert opion. The expert panel was subdivided in 3 multidisciplinary groups which respectively worked upon 3 levels of intervention: comorbidies and lifestyle; acute attack management; management of chronic gout. The original propositions have been translated by each of the multidisciplinary groups and subsequently approved by the whole panel. The identification of the research queries has been conducted through the Delphi technique. In order to classify the items under the 3 levels (comorbidies and lifestyle; acute attack management; long-term management of gout), separate voting for each item has been conducted and the 4 top ranking queries were selected. These 4 queries, which were subsequently rephrased according to the PICO (Population-Intervention-Comparator-Outcome) strategy, where: 1. does the consumption of specific foods and beverages influence the disease outcome (e.g. uricaemia, number of flares, disability, mortality) in patients with gout?; 2. is the administration of oral corticosteroids, with respect to other forms of treatment, effective and safe in patients with an acute attack of gout?; 3. is low-dose colchicine (0.5 mg up to 3 time daily), with respect to higher dose 
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administration, effective and safe in patients with an acute attack of gout?; 4. is febuxostat, with respect to other forms of urate lowering treatment or no treatment at all, effective and safe in patients with chronic gout? A systematic search strategy has been defined for each query. The 4 searches have been undertaken on the main electronic bibliographic databases (Medline, Embase and Cochrane Library), in the timeframe between 1/1/1950 and 25/3/2012 and restricting the search to publications in Italian and English and to studies on human beings. Moreover, the search has been enhanced with a manual search in the proceedings of the 2010 and 2011 EULAR and ACR congresses, and in the reference lists of the studies included from the electonic search. Inclusion criteria have been defined for each query, and subsequently, an ad hoc extraction form has been developed. The article selection for each query has been conducted by a single reviewer (MM, AB, MF and IP). Only studies regarding the clinical aspects of gout were included. Studies on hyperuricaemia were only included when an evaluation of the influence of specific factors (e.g. eating habits) on the onset on gout was conducted. Studies with the following design were included: systematic review and meta-analysis, randomised control trial (RCT) and controlled study for efficacy and safety queries, and also cohort studies, case control and crosssectional studies for risk factor queries. Case reports, narrative reviews and editorials were excluded in all cases. Efficacy and safety data on drugs reported in RCTs have been combined in a metaanalysis where feasible, and presented as standardized mean differences [SMD or effect size (ES)], Number Needed to Treat (NNT) or risk ratio (RR), and relative Confidence Intervals (CI) at 95%. From the clinical perspective, an ES of 0.20 is considered low, 0.5 as moderate and more than 0.80 as high. The NNT is the number of patients who have to be treated in order to obtain the desired effect (or prevent an unwanted effect) in one of them, and therefore a lower value corresponds to higher efficacy. On the basis of the study design, the impact of risk factors has been expressed as RR or odds ratio (OR). The ES calculations and the resulting meta-analyses have been created with Review Manager (Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). The level of evidence for efficacy has been assigned according to the design of the included studies via a preestablished hierarchy (Tab. I). The search results therefore consisted of the highest level of evidence available: for example, if a systematic review of RCTs was available, the existing literature review was updated and studies with a weaker design were excluded. Queries on risk factors or adverse effects were based on both RCTs and observational studies. Studies with direct evidence were first considered, and indirect evidence studies were only analysed when direct evidence studies were unavailable. In order to maintain consistency with Eular recommendations, the strength of recommendation (SOR) was measured for each proposition by utilising the EULAR A-E ordinal scale (A=fully recommended; B=strongly recommended; C=moderately recommended; D=weakly recommended; E=not recommended) and a 0-100 mm visual analogue scale (VAS) (8) , by taking into consideration both the evidence (efficacy, safety and cost-effectiveness) and the clinical experience (feasibility, acceptability and tolerance). The results of each proposition were reported as mean of the VAS with 95% CI and as percentage of fully or strongly recommended propositions (A-B). . A RCT has shown a significant reduction in the number of flares in patients with gout who consumed skimmed milked enriched with certain compounds (glycomacropeptide and lipid extract G600) when compared to a control (lactose), suggesting that these compounds could explain the protective effect of dairy products in individuals with gout (35) . The long-term consumption of coffee in the general population has been associated with a decreased incidence of gout (36, 37) . Recent studies have suggested vitamin C as a protective dietary compound (29, 38) .
Conclusions. There is widespread consensus on the importance of patient education in improving outcome by affecting compliance and lifestyle change (level IV). There is evidence in the general population that consumption of purine-rich foods and beverages containing alcohol and fructose is a risk factor for gout, while consumption of milk, low-fat dairy products, coffee and vitamin C is reported as having a protective effect on gout (level III). Therefore, despite the absence of studies directly assessing the role of diet modification on diseaserelated outcomes in patients with gout, dietary intervention should be considered in the management of gout (level IV).
Associated comorbidity and risk factors such as hyperlipidaemia, hypertension, hyperglycaemia, obesity and smoking should be addressed as an important part of the management of gout. Results from non-controlled studies reported in the EULAR recommendations (10, 11) have shown a dose-dependent response to allopurinol of a lowering of 1 mg of serum uric acid levels for every 100 mg of allopurinol increase. These results support the need of slow titration of the allopurinol dose till the attainment of target levels. A 'dose-escalation' study has shown that a daily dose increment of 300 to 600 mg is associated with serum uric acid levels of <5.5 mg/dL in 78% of patients (68, 69) . Allopurinol can cause potentially serious adverse reactions such as the hypersensitivity syndrome characterised by cutaneous desquamation, fever, hepatitis, eosinophilia, renail failure and a mortality rate of up to 20% (68, 70) . Despite its potential benefit in mild hypersensitivity reactions, desensitisation is not recommended since it is deemed as an obsolete and potentially harmful procedure. Allopurinol is mainly excreted in urine and its mebatolite, oxypurinol, can accumulate to toxic levels in patients with renal insufficiency, therefore, lower starting doses (50-100 mg) are indicated in this group of patients (71) . A low-dose start of allopurinol and gradual increments at 2-4 weeks are recommended in light of efficacy and safety data. Despite lack of supporting experimental data, this regimen reduces the frequency of acute attacks on starting treatment, reduces the incidence of adverse reactions and identifies the patient-specific minimum effective dose required to mantain optimal serum uric acid levels. Despite the lack of experimental data, a daily starting dose of 100 mg with successive increments to doses reaching the therapeutic goal is preferable to a fixed dosage, especially in patients with renal insufficiency (level IV). Alternative urate lowering agents can be considered in certain cases such as allopurinol hypersensitivity (level IV).
Strength of recommendation (95% CI
Febuxostat is an effective alternative to allopurinol which shows greater efficacy and minor adverse effects as urate lowering agent. Starting doses are to be low and increased if necessary. (74, 75) . Data from the first meta-anaylsis has shown a greater likelihood to reach the therapeutic target with febuxostat at 80 mg or more than with 300 mg of allopurinol (Tab. III). 
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The second meta-analysis has shown a higher risk of an acute attack onset with high-dose febuxostat than with allopurinol although this difference was not statistically different at the commonly prescribed febuxostat dosages of 80 mg and 120 mg.
The combined safety data analysis comparing febuxostat and allopurinol has not shown statistically significant difference between 300 mg allopurinol and febuxostat at any single dose, however the combined RR for all combined doses skews slightly in favour of febuxostat [RR: 0.76 (0.59, 0.98)]. In interpreting the above results it is important to consider the inclusion of participants with previous failure with allopurinol treatment and the fixed dose of allopurinol at 300 mg. Additional data from observational studies and from a subanalysis and an observational extension of RCTs has provided further information on the efficacy and safety of febuxostat. An open label extension of a phase II RCT has evaluated the efficacy and safety of febuxostat at 5 years in 116 patients and has shown a lowering of serum uric acid levels to ≤6 mg/dL in 83% of participants and resolution of tophi in 69% at the last followup session with none of the participants experiencing adverse drug reactions. The RCT extension study has compared the safety of 80 mg and 120 mg of febuxostat to 300 mg of allopurinol on a cohort of 1086 patients with gout and hyperuricaemia. Comparative results have shown the superior efficacy of 80 mg of febuxostat on 300 mg of allopurinol [RR 1.76 (1.46, 2.11)] in reaching therapeutic target at 6 months, although such difference in efficacy decreased thereafter; the same study has shown a long-term reduction in the dimensions of tophi and progressive flareup risk reduction with all treatment regimes (76) . A retrospective study on 13 patients has shown a good security profile on individuals with past severe adverse reactions to allopurinol (77) . An increase in the risk of adverse cardiovascular events has not yet been supported by RCT data (78).
Conclusions.
Febuxostat is an effective urate lowering agent (level Ia) in patients with gout and has shown greater efficacy at a dosage of 80 mg or more when compared to allopurinol at the maximum dose of 300 mg in the short-term control of hyperuricaemia (level Ia). Treatment with febuxostat has been shown to be safer in patients with mild or moderate renal insufficiency when compared to treatment with allopurinol (level Ib).
Prophylaxis against acute attack during the first months of urate lowering therapy can be achieved with colchicine (0.5 mg to 1mg daily) and/or NSAIDs. If not contraindicated, low-dose corticosteroids are a feasible alternative in refractory cases or cases of drug intolerance.
Strength of recommendation (95% CI): 87 (81, 93)
Comments. The start of urate lowering therapy can precipitate an acute attack of gout in response to a rapid drug-induced reduction of serum uric acid levels. Therefore, prophylactic treatment is an integral part of appropriate management. The 2006 EULAR recommendations highlighted the administration of oral colchine and/or NSAIDs as first line prophylactic treatment for acute attacks. Two controlled clinical studies have evaluated and shown the prophylactic efficacy of colchicine (79, 80) . A controlled study on patients with gout who have started treatment with allopurinol has compared the efficacy of colchicine (0.6 mg daily) to a placebo and has shown a significant reduction in the number of acute attacks [7/21 vs 17/22, NNT 2 (1-6)] but an increase in adverse gastrointestinal effects (diarrhoea) [RR (95% CI): 8.38 (1.14, 61.38)] during the first three months of therapy with colchicine combined with allopurinol. Another study on 52 patients with intercritical phase gout has compared the efficacy of combined probenecid (500 mg three times daily) and low-dose colchicine (0.5 mg daily) to probenecid monotherapy. Similar efficacy in serum uric acid reduction and safety has been reported for both regimens although a significantly lower number of acute attacks Original article tic options available in Italy. The methodology of Italian recommendations mirrors the one assumed by the EULAR task force and has conserved its strengths. The expert panel was appointed from the whole spectrum of healthcare professionals who could be involved in the management of patients with gout. The outcome of this selection can lead to compliance to these recommendations from clinicians of a different and complimentary background and therefore lead to improved management of gout and comorbidities in a more holistic manner.
The undertaken metholody presents various characteristics of strength which translated into the reliability of results. The review items on which to search for evidence were identified by the experts through a process of consensus with the aim of answering questions deemed relevant from a clinical perspective in the management of the patient with gout. New evidence on the preestablished items has been systematically collected via the Cochrane methodology utilising the same bibliographic research strategy of the EULAR recommendations, and integrating them with other strategies from Cochrane systematic reviews (85, 86) . Such approach guarantees both consistency with the previously collected data and the required systematic methodology for the update with new evidence. The strength of recommendation has been evaluated through the methodology recommended by the EULAR which assigns a level of evidence on the basis of a visual analogue scale and an ordinal scale. Such approach creates a summary of data on efficacy and safety which is combined with the clinical experience and therefore merges evidence and feasibility instead of merely providing grades of recommendations solely based on the design of the available studies.
The Italian recommendations include a number of limitations. Firstly, the review update has been only undertaken for a number of questions identified from the expert panel and therefore other questions assigned a level of priority inferior to the preestablished threshold were not considered. Among these, for example, were the queries on the efficacy and safety of antiplatelets other than aspirin, efficacy and safety of prophylactic low-dose corticosteroids during urate lowering treatment, the use of imaging technology in prognostic stratification and disease monitoring, the effect of stopping urate lowering treatment in patients with optimal long-term control of gout and the establishment of target serum uric acid levels in urate lowering treatment. A further limitation is the compilation of the literature review by a single reviewer. Additionally, the employment of validated scales for quality assurance was not ultimately utilised for a formal selection based on the level of quality acquired from this evaluation. The Italian recommendations literature review has also identified sufficient lack of high level evidence in support of various treatment options which consequently leads to the adoption of different clinical approaches. Such variability translated in low strength of recommendation confidence interval precision for each proposition. The experts believe that the future research agenda is to include a number of aspects which have not been yet enough investigated (Tab. V).
n CONCLUSIONS
The Italian Society of Rheumatology (SIR) has developed an updated version of the 
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EULAR recommendations for the management of patients with gout, adapted to the Italian healthcare system. Finally, 12 propositions were formulated to target the different levels of patient management: comorbidity and lifestyle, management of acute attacks and long-term management of gout. Propositions on long-term management based on the original EULAR recommendations were reformulated by considering the availability of new evidence and the Italian pharmaceutical formulary. The fact that the recommendations were formulated by a multidisciplinary team aids in ensuring good dissemination and their implementation will certainly improve the management of patients with a potentially curable disease such as gout. 
